Studie MOR208C310 - frontMIND

MOR208C310 - frontMIND

A Phase 3, multicenter, randomized, double-blind, placebocontrolled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and highrisk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Z-Nr.: 410

NCT04824092

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung aktiv

Positiv

2021-04-15

Unbekannt / Unbekannt

1

Chemo,Zielgerichtet